Nianhua Ding
Changsha, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer: an exploratory, open-label phase II study.
Journal: International journal of surgery (London, England)
Published: April 15, 2025
ASO Author Reflections: Reflections on the Role of the Systemic Immune-Inflammation Index in Prognostic Assessment in HER2-Positive Metastatic Breast Cancer.
Journal: Annals of surgical oncology
Published: November 15, 2024
Prognostic and predictive significance of neutrophil/lymphocyte ratio for trastuzumab treatment efficacy in HER2-positive breast cancer.
Journal: Scientific reports
Published: October 26, 2024
Prognostic Value of the Baseline Systemic Immune-Inflammation Index in HER2-Positive Metastatic Breast Cancer: Exploratory Analysis of Two Prospective Trials.
Journal: Annals of surgical oncology
Published: July 24, 2024
Systemic immune-inflammation index as a prognostic marker in HER2-positive breast cancer patients undergoing trastuzumab therapy.
Journal: Scientific reports
Published: November 09, 2023
Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial.
Journal: Breast cancer research : BCR
Published: July 24, 2023
A novel CD74-ROS1 gene fusion in a patient with inflammatory breast cancer: a case report.
Journal: Journal of medical case reports
Published: September 11, 2020
Prognostic Roles of Neutrophil-to-Lymphocyte Ratio and Stromal Tumor-Infiltrating Lymphocytes and Their Relationship in Locally Advanced Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.
Journal: Breast care (Basel, Switzerland)
Published: December 12, 2019
Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy.
Journal: BMC cancer
Published: December 11, 2019
Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2-) Breast Cancer.
Journal: Clinical breast cancer
Published: September 21, 2019
EIF2A promotes cell survival during paclitaxel treatment in vitro and in vivo.
Journal: Journal of cellular and molecular medicine
Published: March 09, 2019
Last Updated: 09/26/2026